Disease · MONDO_0010602
Comparisons in its trials51
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 51
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Previously Treated Patients (PTPs) vs Previously Untreated Patients (PUPs): Number of Participants Who Discontinued the Use of Study Drug | 10 of 123 | 5 of 12 | 135 | NCT03169972 | Trial comparisons |
| Previously Treated Patients (PTPs) vs Previously Untreated Patients (PUPs): deaths from any cause | 0 of 123 | 0 of 12 | 135 | NCT03169972 | Trial comparisons |
| Previously Treated Patients (PTPs) vs Previously Untreated Patients (PUPs): serious adverse events | 2 of 123 | 1 of 12 | 135 | NCT03169972 | Trial comparisons |
| Part A: Main Study vs Part B: ITI Portion: Number of Participants With At Least One Clinically Significant Changes in Vital Signs | 0 of 120 | 0 of 7 | 127 | NCT02615691 | Trial comparisons |
| Part A: Main Study vs Part B: ITI Portion: Number of Participants With At Least One Clinically Significant Changes in Clinical Laboratory Parameters | 53 of 120 | 1 of 7 | 127 | NCT02615691 | Trial comparisons |
| Pre-prophylaxis vs Prophylaxis: Number of Participants With Confirmed High Titre Inhibitors (Defined as Inhibitor Titre Above 5 Bethesda Units (BU) | 3 of 55 | 8 of 68 | 123 | NCT02137850 | Trial comparisons |
| Pre-prophylaxis vs Prophylaxis: Number of Participants With Inhibitory Antibodies Against Coagulation Factor VIII (FVIII) | 11 of 55 | 10 of 68 | 123 | NCT02137850 | Trial comparisons |
| Factor On-demand vs Fitusiran 80 mg Prophylaxis: deaths from any cause | 0 of 40 | 0 of 79 | 119 | NCT03417245 | Trial comparisons |
| Factor On-demand vs Fitusiran 80 mg Prophylaxis: serious adverse events | 5 of 40 | 5 of 79 | 119 | NCT03417245 | Trial comparisons |
| BAX 855 Safety Analysis Set vs ADVATE Received Before BAX 855: serious adverse events | 3 of 66 | 0 of 31 | 97 | NCT02210091 | Trial comparisons |
Moroctocog Alfa (AF-CC), RP Cohort: RP Therapy 45 IU/kg vs Moroctocog Alfa(AF-CC),OD and RP Cohort: RP Therapy 25 IU/kg: Number of Participants With Incidence of Less Than Expected Therapeutic Effect (LETE): Routine Prophylaxis Therapy | 3 of 42 | 5 of 51 | 93 | NCT00543439 | Trial comparisons |
Moroctocog Alfa (AF-CC), RP Cohort: RP Therapy 45 IU/kg vs Moroctocog Alfa(AF-CC),OD and RP Cohort: RP Therapy 25 IU/kg: Number of Participants Requiring Prophylaxis Regimen Escalation: Routine Prophylaxis Therapy | 2 of 39 | 1 of 48 | 87 | NCT00543439 | Trial comparisons |
| Recombinant Factor VIII Prophylaxis Treatment vs Recombinant Factor VIII On-demand Treatment: serious adverse events | 9 of 42 | 11 of 42 | 84 | NCT00623480 | Trial comparisons |
| BIVV001: Participants Aged <6 Years vs BIVV001: Participants Aged 6 to <12 Years: Number of Participants With Neutralising Antibodies (Development of Inhibitors) Directed Against Factor VIII | 0 of 38 | 0 of 36 | 74 | NCT04759131 | Trial comparisons |
| BIVV001: Participants Aged <6 Years vs BIVV001: Participants Aged 6 to <12 Years: deaths from any cause | 0 of 38 | 0 of 36 | 74 | NCT04759131 | Trial comparisons |
| BIVV001: Participants Aged <6 Years vs BIVV001: Participants Aged 6 to <12 Years: Number of Participants With Occurrence of Embolic and Thrombotic Events | 0 of 38 | 0 of 36 | 74 | NCT04759131 | Trial comparisons |
| BIVV001: Participants Aged <6 Years vs BIVV001: Participants Aged 6 to <12 Years: serious adverse events | 5 of 38 | 4 of 36 | 74 | NCT04759131 | Trial comparisons |
| Younger Children (0 - 5 Years) [Main Trial] vs Older Children (6 - 11 Years) [Main Trial]: Number of Participants With Inhibitory Antibodies Against Coagulation Factor VIII (FVIII) ≥0.6 Bethesda Units | 0 of 34 | 0 of 34 | 68 | NCT01731600 | Trial comparisons |
| Younger Children£(0-5 Years) vs Older Children£(6-11 Years): deaths from any cause | 0 of 34 | 0 of 34 | 68 | NCT01731600 | Trial comparisons |
| Younger Children£(0-5 Years) vs Older Children£(6-11 Years): serious adverse events | 11 of 34 | 5 of 34 | 68 | NCT01731600 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0010602/comparisons